Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025
Standard BioTools (NASDAQ: LAB) has unveiled new proteomic product innovations at AACR 2025, including the SomaScan Select 3.7K Assay, Single SOMAmer Reagents, and the next-generation CyTOF XT PRO system.
The SomaScan Select 3.7K Assay offers 3,700 unique human protein measurements and covers 70% of FDA standard clinical biomarkers. Single SOMAmer Reagents provide access to approximately 11,000 unique DNA-based reagents for protein measurement. The CyTOF XT PRO System enables simultaneous analysis of 50-plus biomarkers with up to 4x faster throughput.
The company will host a panel discussion on April 28 titled 'Lost in Omics? Navigating the Path from Protein Discovery to Healthcare Impacts.' Additionally, 90 scientific posters and presentations powered by Standard BioTools' proteomic portfolio will be presented at AACR 2025.
Standard BioTools (NASDAQ: LAB) ha presentato nuove innovazioni nei prodotti proteomici all'AACR 2025, tra cui il SomaScan Select 3.7K Assay, i Single SOMAmer Reagents e il sistema di nuova generazione CyTOF XT PRO.
Il SomaScan Select 3.7K Assay offre la misurazione di 3.700 proteine umane uniche e copre il 70% dei biomarcatori clinici standard FDA. I Single SOMAmer Reagents permettono l’accesso a circa 11.000 reagenti unici basati su DNA per la misurazione delle proteine. Il sistema CyTOF XT PRO consente l’analisi simultanea di oltre 50 biomarcatori con una velocità fino a 4 volte superiore.
L’azienda organizzerà una tavola rotonda il 28 aprile intitolata «Lost in Omics? Navigating the Path from Protein Discovery to Healthcare Impacts». Inoltre, all'AACR 2025 saranno presentati 90 poster scientifici e presentazioni basati sul portafoglio proteomico di Standard BioTools.
Standard BioTools (NASDAQ: LAB) ha presentado nuevas innovaciones en productos proteómicos en AACR 2025, incluyendo el SomaScan Select 3.7K Assay, los Single SOMAmer Reagents y el sistema de próxima generación CyTOF XT PRO.
El SomaScan Select 3.7K Assay ofrece la medición de 3,700 proteínas humanas únicas y cubre el 70% de los biomarcadores clínicos estándar de la FDA. Los Single SOMAmer Reagents brindan acceso a aproximadamente 11,000 reactivos únicos basados en ADN para la medición de proteínas. El sistema CyTOF XT PRO permite el análisis simultáneo de más de 50 biomarcadores con un rendimiento hasta 4 veces más rápido.
La compañía organizará un panel de discusión el 28 de abril titulado «Lost in Omics? Navigating the Path from Protein Discovery to Healthcare Impacts». Además, en AACR 2025 se presentarán 90 pósters científicos y presentaciones impulsadas por el portafolio proteómico de Standard BioTools.
Standard BioTools (NASDAQ: LAB)는 AACR 2025에서 SomaScan Select 3.7K Assay, Single SOMAmer Reagents, 차세대 CyTOF XT PRO 시스템 등 새로운 단백질체 제품 혁신을 공개했습니다.
SomaScan Select 3.7K Assay는 3,700개의 고유한 인간 단백질 측정을 제공하며 FDA 표준 임상 바이오마커의 70%를 포함합니다. Single SOMAmer Reagents는 약 11,000개의 고유한 DNA 기반 단백질 측정 시약에 접근할 수 있게 합니다. CyTOF XT PRO 시스템은 50개 이상의 바이오마커를 동시에 분석하며 처리 속도가 최대 4배 빠릅니다.
회사는 4월 28일 'Lost in Omics? Navigating the Path from Protein Discovery to Healthcare Impacts'라는 제목의 패널 토론을 주최할 예정입니다. 또한 AACR 2025에서 Standard BioTools의 단백질체 포트폴리오를 기반으로 한 90개의 과학 포스터와 발표가 진행됩니다.
Standard BioTools (NASDAQ : LAB) a dévoilé de nouvelles innovations en produits protéomiques lors de l’AACR 2025, incluant le SomaScan Select 3.7K Assay, les Single SOMAmer Reagents et le système de nouvelle génération CyTOF XT PRO.
Le SomaScan Select 3.7K Assay offre la mesure de 3 700 protéines humaines uniques et couvre 70 % des biomarqueurs cliniques standards approuvés par la FDA. Les Single SOMAmer Reagents donnent accès à environ 11 000 réactifs uniques à base d’ADN pour la mesure des protéines. Le système CyTOF XT PRO permet l’analyse simultanée de plus de 50 biomarqueurs avec un débit jusqu’à 4 fois plus rapide.
L’entreprise organisera une table ronde le 28 avril intitulée « Lost in Omics? Navigating the Path from Protein Discovery to Healthcare Impacts ». Par ailleurs, 90 posters scientifiques et présentations basés sur le portefeuille protéomique de Standard BioTools seront présentés lors de l’AACR 2025.
Standard BioTools (NASDAQ: LAB) hat auf der AACR 2025 neue Innovationen im Bereich der Proteomik vorgestellt, darunter den SomaScan Select 3.7K Assay, Single SOMAmer Reagents und das nächste Generation CyTOF XT PRO System.
Der SomaScan Select 3.7K Assay ermöglicht die Messung von 3.700 einzigartigen menschlichen Proteinen und deckt 70 % der von der FDA standardisierten klinischen Biomarker ab. Die Single SOMAmer Reagents bieten Zugang zu etwa 11.000 einzigartigen DNA-basierten Reagenzien zur Proteinmessung. Das CyTOF XT PRO System erlaubt die gleichzeitige Analyse von über 50 Biomarkern mit bis zu viermal höherer Durchsatzrate.
Das Unternehmen veranstaltet am 28. April eine Podiumsdiskussion mit dem Titel „Lost in Omics? Navigating the Path from Protein Discovery to Healthcare Impacts“. Zudem werden auf der AACR 2025 90 wissenschaftliche Poster und Präsentationen vorgestellt, die auf dem proteomischen Portfolio von Standard BioTools basieren.
- Launch of three new advanced proteomic products expanding company's portfolio
- SomaScan Select 3.7K Assay covers 70% of FDA standard clinical biomarkers
- CyTOF XT PRO System offers 4x faster throughput for clinical trials
- Strong scientific validation with 90 presentations featuring company's technology
- None.
Insights
Standard BioTools unveils three strategic proteomics innovations enhancing research capabilities across cancer studies, strengthening their product portfolio without immediate revenue impact.
Standard BioTools' announcement at AACR 2025 represents a significant expansion of their proteomics technology portfolio with three distinct innovations targeting translational and clinical research applications. The SomaScan Select 3.7K Assay delivers a cost-optimized solution measuring approximately 3,700 unique human proteins while covering
Their new Single SOMAmer Reagents offer researchers access to approximately 11,000 unique DNA-based reagents for protein detection, providing an alternative to traditional antibodies with enhanced reproducibility and minimal batch variability. This addresses a critical pain point in protein research where consistency between experiments is essential.
The next-generation CyTOF XT PRO system delivers the most substantial technical advancement with up to 4x faster throughput and simultaneous analysis of 50+ biomarkers, specifically engineered to accelerate clinical trial workflows. The inclusion of 21 CFR Part 11 compliant software indicates a strategic focus on pharmaceutical customers conducting regulated clinical research.
The company's strong presence at AACR with 90 scientific presentations demonstrates significant researcher adoption of their existing technologies. These launches collectively strengthen Standard BioTools' competitive positioning across the proteomics workflow spectrum - from discovery through clinical development - by offering researchers enhanced capabilities in protein measurement, detection sensitivity, and high-parameter immune profiling.
Standard BioTools launches three strategic proteomics products targeting clinical research markets, potentially expanding revenue streams without immediate financial impact.
Standard BioTools' multi-pronged product launch strategy demonstrates a calculated approach to capturing greater market share across the proteomics workflow ecosystem. By simultaneously introducing new offerings across consumables (SomaScan Select and SOMAmer reagents) and instrumentation (CyTOF XT PRO), the company is methodically expanding its addressable market while creating potential recurring revenue opportunities.
The SomaScan Select 3.7K Assay represents a classic market segmentation strategy - offering
Most strategically significant is the CyTOF XT PRO system's explicit focus on clinical trial applications, with features specifically designed to support regulatory compliance (21 CFR Part 11) and accelerate research timelines. This positions Standard BioTools to capitalize on the pharmaceutical industry's growing investment in proteomics-based biomarker discovery and patient stratification.
The company's substantial scientific presence at AACR (90 presentations) serves as a leading indicator of research community engagement with their technology platform. This broad adoption within academic and pharmaceutical research settings creates a critical foundation for commercial traction with these new product offerings.
While the announcement contains no specific financial projections or commercialization timelines, these launches align with CEO Michael Egholm's stated strategy of expanding across "consumables, instruments and services" to strengthen their proteomics leadership position in translational and clinical research markets.
Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next-generation drug development
Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from target discovery to clinical development
SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of new and enhanced proteomic product offerings at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025. These advancements – including the SomaScan™ Select 3.7K Assay, Single SOMAmer™ Reagents and the next-generation CyTOF™ XT PRO system – are purpose-built to support translational and clinical research across oncology and other therapeutic areas.
“At Standard BioTools, we are focused on delivering high-impact solutions that enable our customers to uncover novel biological insights and accelerate development of more effective therapeutics,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “The launches we’re announcing at AACR reflect our strategy to lead in proteomics by expanding our portfolio across consumables, instruments and services – helping researchers move faster, make smarter decisions and drive real impact in translational and clinical research.”
The SomaScan Platform: Next-generation assays and consumable reagents for translational research applications
SomaScan Select 3.7K Assay: a cost-effective, high-plex solution delivering approximately 3,700 unique human protein measurements. This targeted assay is designed for researchers seeking translational depth without full-plex cost while maintaining exceptional performance. Key highlights include:
- Covers
70% of FDA standard clinical biomarkers, making it a powerful tool for researchers investigating oncology, cardiometabolic disorders, immunology and other therapeutic areas - Compatible with a variety of sample types, including human and non-human serum, plasma, cell lysates and tissue homogenates
- Offered through the Standard BioTools™ CAP/CLIA-accredited laboratory in Boulder, Colo.
Single SOMAmer Reagents: a powerful antibody alternative for affinity-based confirmatory methods (for example, ELISA, mass spectrometry pull-down assays) enabling singleplex protein measurement and low-abundance target detection. These new reagents offer:
- Access to approximately 11,000 unique, chemically synthesized, DNA-based reagents
- Superior reproducibility with low batch-to-batch variability
- High sensitivity with the capability of detecting rare proteins
CyTOF Technology: High-parameter immune profiling to accelerate clinical development
CyTOF XT PRO System: a next-generation platform designed to maximize clinical trial efficiency by delivering clearer, more complete and more reliable patient response data for drug development. Key enhancements include:
- The widest immune coverage, simultaneously analyzing 50-plus biomarkers for unparalleled understanding of drug mechanism and clinical response
- Streamlined workflow with up to 4x faster throughput, simplified sample prep and rapid panel design to accelerate research timelines from concept to insight in weeks
- New software that supports 21 CFR Part 11 compliance for clinical trial researchers
Standard BioTools at AACR
As part of its participation at AACR, Standard BioTools will host a panel discussion on Monday, April 28 from 12:30–1:30 pm in the Exhibitor Spotlight Theater. This panel will explore the future of proteomics and its critical role in translational research, biomarker discovery and clinical decision making.
Session title: Lost in Omics? Navigating the Path from Protein Discovery to Healthcare Impacts
Moderated by: Stephen Williams, MD, PhD – Chief Medical Officer, Standard BioTools
Featuring expert panelists:
- Elio Riboli, MD, MPH, HonFPH, FMedSci (Imperial College London)
- Brice Gaudilliere, MD, PhD (Stanford University)
- Wendy Fantl, PhD (Novartis)
- Michal Harel, PhD (OncoHost)
Standard BioTools and collaborators will present findings from key studies demonstrating the critical role proteomics plays in translational and clinical oncology research at AACR 2025, with 90 scientific posters and presentations powered by the Standard BioTools proteomic portfolio. These studies highlight the power of high-plex, single-cell and spatial proteomics in uncovering predictive biomarkers, elucidating mechanism of action and enabling patient stratification in cancer studies.
Standard BioTools invites AACR attendees to the highlighted poster and oral sessions, which can be found at: standardbio.com/aacr-2025.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB) has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook and LinkedIn.
For Research Use Only. Not for use in diagnostic procedures.
Patent and License Information: www.standardbio.com/legal/notices.
Trademarks: www.standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2025 Standard BioTools Inc. All rights reserved.
Media contact
Emilia Costales
emilia.costales@standardbio.com
Investor contact
David Holmes
ir@standardbio.com
FAQ
What new products did Standard BioTools (LAB) announce at AACR 2025?
How many protein measurements can the new SomaScan Select 3.7K Assay from LAB analyze?
What are the key features of Standard BioTools' (LAB) new CyTOF XT PRO System?
How many scientific presentations will feature Standard BioTools' (LAB) proteomic portfolio at AACR 2025?
